Anavex Life Sciences Corp (AVXL)

[nidan7500]

Too much of a good things...is just fine:

“This is the first full genomic analysis of ANAVEX®2-73 in Alzheimer’s disease which resulted in the identification of actionable genetic variants, bringing us one step closer to realizing the full potential of a precision medicine and precision pharmacology approach to treating this devastating disease,” said Professor Harald Hampel, M.D., Ph.D., MA, MSc, AXA Research Fund & Sorbonne University Excellence Chair, Department of Neurology, Sorbonne University, Paris. He is the speaker of the Alzheimer Precision Medicine Initiative (APMI). Professor Hampel continues that “We look forward to advancing the ANAVEX®2-73 program and believe that a biomarker-guided approach to targeted drug development that allows to select those patients who will respond best to treatment will result in improved clinical results.”

Consider that HH has been working/leading this P.M. process initiative for a long time. He has pushed the FDA and other process leaders to wake up and smell the coffee. He now has an opportunity to relate results of P.M. process. Yes, we acknowledge it is early yet and we still have a lot to learn , BUT, it is a lot better that ...sorry, you CNS disease is untreatable. This may be a Fleming moment.

IMO, the best part of this first step is where it leads. Now, the best minds will have a tool suite and process which seems certain to lead to a cascade of binary events for CNS disease treatments while AVXL have front row seats. Pilots and crews report to your ready rooms.